Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look ...

Hims & Hers Health ranks highest in Revenue Growth among its peers. It also leads in Gross Profit margin. However, it has the ...

Hims stock is climbing back from a steep drop within a base. Shares have climbed nearly 29% during the month and outperformed ...

Hims & Hers Health, Inc. HIMS is scheduled to report second-quarter 2025 results on Aug. 4, after the closing bell. In the ...

In this photo illustration, a person holds a smartphone displaying the logo of Hims & Hers Health Inc. (NYSE: HIMS), an ...

Hims & Hers remains a compelling long-term play, with a resilient subscription-driven model, 85%+ retention, and 2.4 million ...

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the Stocks With Huge Catalysts on the Horizon. On July 9, Hims & Hers Health, ...

According to Benzinga Pro, Hims & Hers Health's peer group average for short interest as a percentage of float is 8.31%, which means the company has more short interest than most of its peers. Did you ...

Unlike traditional care models that often leave patients to navigate treatment alone, Hims & Hers delivers access to a ...

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to controversial practices around the sale of compounded drugs. These drugs are ...

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending shares of the U.S. telehealth company plunging more than 30%.

Hims & Hers is a telemedicine platform that offers patients access to a variety of medications, including for skin care, anxiety, sexual health, and even weight loss.